During interactions with the FDA, Anacor came to an agreement regarding the content and format of the proposed NDA for tavaborole. It discussed matters with the regulatory body related to the safety, ...

Anacor Pharmaceuticals announced positive preliminary results from the first of two Phase 3 trials of tavaborole, its topical anti-fungal for onychomycosis, a fungal infection of the nail and nail bed ...

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has successfully completed its pre-NDA (New Drug Application) communications with the Food and Drug Administration (FDA) related to ...

With the FDA accepting the NDA, a response regarding tavaborole should be out by Jul 29, 2014. The NDA filing was based on two phase III studies on tavaborole in the onychomycosis indication, namely, ...

The US Food and Drug Administration (FDA) on July 7 approved an antifungal called tavaborole 5% solution (Kerydin, Anacor Pharmaceuticals) for the topical treatment of toenail onychomycosis.

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered seven ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) today announced positive preliminary results from the second of two Phase 3 trials of tavaborole (known as Study 302).

) announced today that its abstract “Pivotal Phase 3 Safety and Efficacy Results of Tavaborole (Formerly AN2690), a Novel Boron-Based Molecule for the Topical Treatment of Toenail Onychomycosis” was ...

Anacor Pharmaceuticals announced positive preliminary results from the second of two Phase 3 studies of tavaborole (Study 302). Tavaborole is a topical anti-fungal for the treatment of onychomycosis, ...

Anacor Pharmaceuticals, Inc. 's ( ANAC) pipeline includes several topical candidates including an anti-fungal onychomycosis candidate, tavaborole (AN2690). In Jul 2013, Anacor submitted a New Drug ...